🏅 FDA Orphan Designation

Valchlor

meclorethamine

Manufacturer: Helsinn Birex Pharmaceuticals Ltd.

Indicated for:

Classic mycosis fungoidesOrphanHydroa vacciniforme-like lymphoma

FDA-Approved Indications (2)

Classic mycosis fungoidesOrphan Designation

Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

Hydroa vacciniforme-like lymphoma

VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy

Population: patients who have received prior skin-directed therapy

Indications & Usage

1 INDICATIONS AND USAGE VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy ( 1 ).

💙 Support Programs

View all →

VALCHLOR

Helsinn

Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.